Andrea Palm, President Biden’s pick to be the number two official at the U.S. Health and Human Services Department (HHS), pledged during her U.S. Senate confirmation hearing this morning to make sure that the 340B program “is working as it is supposed to be working,” in response to a senior Republican senator’s concerns about drugmakers denying 340B discounts on drugs dispensed by contract pharmacies and pharmacy benefit managers (PBMs) imposing conditions on 340B hospitals’ drug reimbursement.
During the Senate Finance Committee hearing, Senate Minority Whip John Thune (R-S.D.), second in GOP seniority only to Minority Leader Mitch McConnell (R-Ky.), asked Palm how HHS would respond to such drug manufacturer and PBM actions if confirmed.
Andrea Palm, President Biden’s pick to be the number two official at the U.S. Health and Human Services Department (HHS), pledged during her U.S. Senate confirmation hearing this morning to make sure that the 340B “is working as it is supposed to be working,” in response to a senior Republican senator’s concerns about drugmakers denying 340B discounts on drugs dispensed by contract pharmacies and pharmacy benefit managers (PBMs) imposing conditions on 340B hospitals’ drug reimbursement.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
